Of particular concern, the PD-1 inhibitor, camrelizumab (SHR-1210), has been observed to have a highly specific AE known as capillary hemangioma, which appears after the initiation of treatment and regresses spontaneously both during and after treatment, with no remarkable effects on the anti-tumor efficacy or safety of the drug (97). Here, PDCD1 is linked to neoplasm.